In this review:
This review discusses the evidence in support of secukinumab (Cosentyx®), a high-affinity, human, monoclonal antibody that selectively binds to interleukin-17A to inhibit its proinflammatory effects, for the management of active psoriatic arthritis (PsA), and active ankylosing spondylitis (AS), focussing on outcomes from the phase 3 studies in patients with psoriatic arthritis (FUTURE trials), and ankylosing spondylitis (MEASURE trials), as well as data from long-term follow-up of up to 5 years. From 1 May 2021, access to secukinumab is widened to cover two rheumatological disorders, with secukinumab funded as a first-line biologic in PsA and as a second-line agent in AS. This review is sponsored by an educational grant from Novartis (NZ) Ltd.
Please login below to download this issue (PDF)